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Background: Fatty liver index (FLI) was recently established to predict non-alcoholic fatty liver disease (NAFLD) in
general population, which is known to be associated with coronary artery atherosclerotic disease (CAD).
This study aims to investigate whether FLI correlates with NAFLD and with newly diagnosed CAD in a special
Chinese population who underwent coronary angiography.
Methods: Patients with CAD (n = 231) and without CAD (n = 482) as confirmed by coronary angiography were
included. Among them, 574 patients underwent B-ultrosonography were divided into NAFLD group (n = 209) and
non-NAFLD group (n = 365). Correlation between FLI and NAFLD was analyzed using pearson’s correlation. The
associations between FLI and NAFLD as well as CAD were assessed using logistic regression. The predictive
accuracy of FLI for NAFLD was evaluated using receiver operating characteristics (ROC) curve analysis.
Results: FLI was significantly higher in NAFLD group (37.10 ± 1.95) than in non-NAFLD group (17.70 ± 1.04), P < 0.01.
FLI correlated with NAFLD (r = 0.372, P < 0.001). The algorithm for FLI had a ROC-AUC of 0.721 (95% CI: 0.678–0.764) in
the prediction of NAFLD. Logistic regression analysis showed that FLI was associated with NAFLD (adjusted OR = 1.038,
95% CI: 1.029-1.047, P < 0.01). The proportion of patients with CAD did not differ among the groups of FLI≤ 30 (32.3%),
30-60 (31.0%), and ≥60 (35.3%). No significant association was found between FLI and CAD (adjusted OR = 0.992,
95% CI: 0.981-1.003 in men and OR = 0.987, 95% CI: 0.963-1.012 in women, P > 0.05).
Conclusions: FLI showed good correlation with NAFLD in patients who underwent coronary angiography, but not
with newly diagnosed CAD. This might be underestimated because some patients in non-CAD group may have other
underlying cardiovascular diseases.
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Non-alcoholic fatty liver disease (NAFLD) is a progres-
sive problem in Asia-Pacific region [1]. The prevalence
of NAFLD is increasing to about 15-20% in cities like
Shanghai, Guangzhou and Hong Kong in China recently
[2]. It is associated with metabolic disorders of lipids,* Correspondence: gracefen@gmail.com
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reproduction in any medium, provided the orhypertension, diabetic mellitus and coronary arterial ath-
erosclerotic disease (CAD). CAD is one of the leading
causes of death from NAFLD [3-5]. Thus, prediction of
NAFLD at earlier stage is important in prevention of the
inherent process of NAFLD and the associated fatal dis-
eases such as CAD.
So far, the diagnosis of NAFLD is based on computer-
ized tomography (CT) scanning, magnetic resonance
spectroscopy (MRS), B-ultrasonography and even liver
biopsy. However, most subjects with NAFLD do not
have symptoms, especially at the very early stage, whichtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Fatty liver index (FLI) was significantly higher in patients
with NAFLD than in patients without NAFLD (non-NAFLD), 37.10 ±
1.95 vs. 17.70 ± 1.04, P< 0.01.
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Bedogni et al [6] established a formula to calculate fatty
liver index (FLI) based on triglycerides, body mass index
(BMI), gamma-glutamyltrasnferase (GGT) and waist cir-
cumference (WC) to predict NAFLD in Italian popula-
tion. These variables are risk factors for CAD as well.
Therefore, whether FLI can be used as a marker for the
prediction of CAD development is worth being explored.
The aim of this study is to evaluate whether FLI is able
to predict NAFLD in a special Chinese population who
underwent coronary angiography and to investigate whe-
ther FLI is associated with newly diagnosed CAD.
Methods
Study subjects and procedure
This was a cross-sectional study. From January 2007 to
September 2011, consecutive patients with suspected
CAD (ie, those with angina or abnormal exercise stress
test results) who presented for the first time for coronary
angiography were recruited in this study. Patients under-
went coronary angiography for reasons as congenital heart
disease, congestive heart failure, cardiomyopathy and
valvular heart diseases were excluded. According to cri-
teria of National Institutes of Health Clinical Research
Network [1,7], patients with alcohol intake >140 g/week
in male or >70 g/week in female were not included in the
study. Patient with other causes such as viral hepatitis,
drug induced hepatitis, autoimmune hepatitis, etc., were
not included either. Finally, 713 patients were included
in the study. In accordance with American College of
Cardiology/American Heart Association guidelines, pa-
tients were defined as CAD positive (CAD group: n = 231,
male/female: 171/60) if equal to or more than 50% diam-
eter stenosis in any one of the major coronary arteries was
found on coronary angiography. If no stenosis was ob-
served, those patients were defined as non-CAD (non-
CAD group: n = 482, male/female: 215/267). We did not
include patients with stenosis less than 50%, because these
lesions may progress, and eventually, patients with no sig-
nificant obstructions have significantly more cardiovascu-
lar events during follow-up than those with truly normal
coronary angiograms [8].
Among 713 patients, 574 patients underwent B-type
ultrasonography, who were accordingly classified into
NAFLD group (n = 209, male/female: 113/96) and non-
NAFLD group (n = 365, male/female: 193/172). The diag-
nostic criteria for steatosis under B-type ultrasound was
indicated by diffusely increased echogenicity (“bright”)
liver with liver echogenicity greater than kidney, with vas-
cular blurring, and deep attenuation of ultrasound signal
[9,10]. BMI was calculated by weight/height2 (kg/m2). FLI
was calculated by previous reported formula [6].
The study protocol was approved by Ethical Commit-
tee at Ruijin Hospital and written informed consents toparticipate in the study were obtained from all the pa-
tients. The study was performed in accordance with the
Declaration of Helsinki.
Statistical analysis
Continuous variables were presented as means ± S.E.M
and compared by t-test between groups. Categorical
variables were summarized as numbers of subjects
(percentage) and compared by χ2 test between groups.
Cochran-Armitage trend tests were also performed if
there were more than two categorical variables. The pre-
dictive accuracy of FLI for NAFLD was evaluated using
receiver operating characteristics (ROC) curve analysis
by DeLong method. In addition, an area under the ROC
curve (AUC) with 95% confidence intervals (CI) was cal-
culated for different markers. A correlation between FLI
with NAFLD was analyzed with Pearson’s correlation.
Associations between FLI and NAFLD as well as CAD
were analyzed by logistic regression analysis, respectively.
Covariates included age, gender, FLI, ALT, AST, alkaline
phosphatase (ALP), total cholesterol (TC), HDL-C, LDL-
C, fasting plasma glucose (FPG), history of hypertension,
history of diabetic mellitus, and history of dyslipidemia.
Data were expressed as odds ratio (OR) with 95% CI were
calculated. All analyses were carried out with SPSS version
17.0. The statistical significance was set at P < 0.05. All
P values were two-sided.
Results
The association between FLI and NAFLD
The clinical characteristics between NAFLD and non-
NAFLD groups were shown in Additional file 1: Table S1.
Patients with NAFLD had significantly higher FLI
(37.10 ± 1.95) than patients without NAFLD (17.70 ±
1.04), P < 0.01, Figure 1. According to Bedogni’s ‘rule in
and rule out’ criteria [6], we divided the patients into
Figure 2 AUC-ROC of FLI for prediction of fatty liver (value = 0.721,
95% CI: 0.678-0.764). FLI, fatty liver index; AUC, area under curve; ROC:
receiver operating curve.
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The clinical characteristics among three FLI categories
were shown in Additional file 1: Table S2. The pro-
portion of patients with NAFLD was 74.6% (53/71) in
group with FLI ≥ 60, 48.3% (56/116) in group with FLI
30-60, and 25.8% (100/387) in group with FLI ≤ 30
(Cochran-Armitage trend test: P < 0.01), Table 1.
The model for FLI had a ROC-AUC value of 0.721
(95% CI: 0.678-0.764, Figure 2) in the prediction of
NAFLD. The accuracy of FLI in the prediction of
NAFLD was better than any single variable in the for-
mula except BMI (Figure 2). Pearson’s correlation
showed FLI correlated with NAFLD (r = 0.372, P <
0.001). Using multivariate Logistic regression analysis,
we found that FLI was associated with NAFLD (age-,
sex-adjusted OR = 1.038, 95% CI: 1.029-1.047, P < 0.01)
(Table 2). History of dyslipidemia, diabetic mellitus, and
hypertension were also factors associated with an in-
creased risk of NAFLD (Table 2). To minimize the influ-
ence of drug therapy on the development of NAFLD, a
further analysis adjusted for anti-hyperlipidemia and dia-
betic mellitus drugs was performed. The result showed
that FLI was still associated with NAFLD (adjusted OR =
1.038, 95% CI: 1.028-1.049, P < 0.01).
Multivariate logistic regression analysis on the factors
associated with CAD
The clinical characters between CAD group and non-
CAD group were shown in Additional file 1: Table S3.
Unexpectedly, no significant difference was observed in
the proportion of patients with CAD among groups with
FLI ≤ 30, 30-60 and ≥60, which was 32.3% (156/483),
31.0% (45/145) and 35.3% (30/85) (Cochran-Armitage
trend test: P > 0.05), respectively (Table 3).
In the multivariate Logistic regression analysis, we found
that both in males and females, older age, higher total
cholesterol, were common factors associated with an in-
creased risk of CAD (Table 4). Higher HDL-C was associ-
ated with a decreased risk of CAD (Table 4). However, no
significant association was found between FLI and CAD
in either males or females (adjusted OR = 0.990, 95% CI:
0.980-1.001 in men and OR = 0.988, 95% CI: 0.965-1.012
in women, P > 0.05). In this study, there were 85.5% of pa-
tients in the non-CAD group and 95.7% of patients in theTable 1 Distribution of NAFLD and non-NAFLD subjects in
different FLI categories
FLI ≤ 30 FLI 30-60 FLI ≥ 60 P value*
(n = 387) (n = 116) (n = 71)
NAFLD 100 (25.8%) 56 (48.3%) 53 (74.6%) <0.01
Non-NAFLD 287 (74.2%) 60 (51.7%) 18 (25.4%) <0.01
*Cochran-Armitage test for trend between three FLI categories.CAD group prescribed with anti-hyperlipidemia drugs.
On the other hand, 12.9% of patients in the non-CAD
group and 13.4% of patients in the CAD group were
treated with anti-diabetic mellitus drugs (Additional file 1:
Table S3). To minimize the influence of drug therapy on
the metabolism of liver, a further analysis was performed
after adjusted for drug therapy. However, FLI was not as-
sociated with CAD in either gender (Table 4).Table 2 Multivariate logistic regression analysis of factors
associated with NAFLD
OR (95% CI) P value
FLI 1.038 (1.029-1.047) < 0.01
History of hypertension 1.627 (1.051-2.519) 0.029
History of diabetic mellitus 1.890 (1.190-3.003) 0.007
History of dyslipidemia 1.414 (1.006-2.217) 0.047
Table 3 Distribution of patients with and without CAD in
different FLI categories
FLI ≤ 30 FLI 30-60 FLI ≥ 60 P value*
(n = 483) (n = 145) (n = 85)
CAD (n = 231) 156 (32.3%) 45 (31.0%) 30 (35.3%) >0.05
Non-CAD (n = 482) 327 (67.7%) 100 (69.0%) 55 (64.7%) >0.05
*Cochran-Armitage test for trend between three FLI categories.
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Fatty liver is usually diagnosed by CT scanning, MRS or
B-ultrosonography. Although pathological diagnosis by
liver biopsy is a golden standard, it is invasive and
not feasible for large population study. FLI was first
established by Bedogni et al [6] based on data from
Italian general population. It is a simple way to calculate
the possibility of fatty liver with only four parameters
and reached an accuracy of 0.84 (95% CI: 0.81-0.87).
BMI, WC, TG and GGT are variables usually easy to ob-
tain. However, due to variation of ethnicity, dietary and
environmental factors, the cut-off for waist and BMI is
different for the Asian people [11,12]. Thus, FLI needs
to be validated when used in a different population.
With the same diagnostic criteria for fatty liver disease
(by ultrasonography) [6], we also showed a good correl-
ation between FLI and non-alcoholic fatty liver disease
(pearson’s correlation r = 0.372, P < 0.001) in a special
Chinese population who underwent coronary angiog-
raphy. The accuracy of FLI was relatively lower (AUC-
ROC value = 0.721, 95% CI: 0.678-0.764) than that of
Bedogni et al’s study, but was nearly the same as that of
Korean general population (accuracy of 0.785, 95% CI:
0.728–0.842) [13]. The results of our study provided fur-
ther evidences that FLI could be considered as an easyTable 4 Multivariate logistic regression analysis of factors ass
Men (n = 386)
OR (95% CI) OR (95
Age 1.049 (1.021–1.077)** 1.047 (1.01
Smoking 1.404 (0.760–2.593) 1.390 (0.7
Alcohol intake 0.441 (0.243–0.801)** 0.451 (0.24
History of hypertension 1.289 (0.714–2.328)* 1.079 (0.5
History of dyslipidemia 2.034 (1.169–3.538)* 1.996 (1.14
History of DM 0.379 (0.163–0.883) 0.419 (0.1
ALP 1.000 (0.986–1.015) 0.999 (0.9
TC 1.745 (1.393–2.185)** 1.752 (1.39
HDL 0.275 (0.097–0.785)* 0.305 (0.10
FPG 1.282 (1.052–1.563)* 1.264 (1.03
FLI 0.990 (0.980–1.001) 0.991 (0.9
a: adjusted for anti-hyerlipidimia and diabetic mellitus drug therapy.
* represents P < 0.05 and ** represents P < 0.01.and useful marker for screening fatty liver subjects in
both general and special population.
Patients with NAFLD were more likely to have CAD
as shown in both retrospective and prospective studies
[14,15]. CAD was also the common cause of death for
NAFLD in population-based cohort studies [16-18] and
follow-up studies [19,20]. In a 13-year follow up study
[21], CAD was shown to be the main cause of death in
patients with NAFLD confirmed by liver biopsy. The
underlying mechanism linked between NAFLD and
CAD could be insulin resistance, lipid disorders, inflam-
mation, etc [22,23]. Furthermore, NAFLD is considered as
the hepatic manifestation of metabolic syndrome [23]
which is believed to be a risk factor for CAD. These
accumulated evidences suggested that physicians and re-
searchers had gradually drawn attention to the relationship
between NAFLD and CAD in recent years.
Based on the good correlation between FLI and NFALD
in patients who underwent coronary angiography, the
second aim of our study is to investigate whether FLI was
related with CAD. In Calori et al’s prospective study [24],
they showed that FLI was associated with cardiovascular
disease-related mortality and cancer-related mortality after
15-year follow-up of 2,074 Caucasian individuals in three
Italian municipalities. Another study of Gastaldelli et al
[25] found that increased intima media thickness, coron-
ary heart disease risk (evaluated by Framingham risk
score), and reduced insulin sensitivity were associated with
high values of FLI in RISC population (also a European
Caucasian population). According to International Classi-
fication of Diseases [26], total cardiovascular diseases
included not only CAD but also other diseases such as
disorders of the peripheral vascular system, disease of the
aorta and its branches, and congenital heart disease, etcociated with CAD
Women (n = 327)
% CI)a OR (95% CI) OR (95% CI)a
9–1.075)** 1.061 (1.019–1.106)** 1.055 (1.012–1.100)*
48–2.582) 0.759 (0.122–4.729) 0.750 (0.120–4.689)
6–0.828)** 3.384 (0.416–27.532) 2.858 (0.357–22.863)
79–2.011) 2.774 (0.989–7.779) 1.850 (0.638–5.359)
2–3.489)* 1.494 (0.718–3.105) 1.656 (0.781–3.512)
46–1.206) 0.612 (0.237–1.581) 0.925 (0.231–3.710)
84–1.014) 0.997 (0.981–1.014) 0.996 (0.979–1.013)
5–2.200)** 1.292 (1.007–1.658)* 1.293 (1.005–1.664)*
4–0.894)* 0.191 (0.051–0.710)* 0.196 (0.052–0.742)*
6–1.543)* 1.224 (0.981–1.526) 1.348 (1.050–1.731)*
80–1.002) 0.988 (0.965–1.012) 0.985 (0.961–1.010)
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the blockage of one or more of the coronary arteries that
supply blood to the heart which usually is caused by
atherosclerosis. However, no study has evaluated the rela-
tionship between FLI and CAD till now. In order to differ-
entiate CAD with other cardiovascular disorders, we
chose coronary angiography as a golden standard. Unfor-
tunately, we could not find the correlation between FLI
and CAD in either gender. Because there was no informa-
tion of coronary angiography provided in the other two
studies, the certain relationship between FLI and CAD in
those studies could not be speculated. The patients
enrolled in our study were suspicious of CAD, but not the
general population. This may be one of the reasons lead-
ing to the differences in results between our study and
the aforementioned two studies [24,25]. On the other
hand, patients in the control group (non-CAD patients)
with negative findings of coronary angiography were
different from subjects in general population; some of
them might have other cardiovascular diseases, which
might lead to the underestimation of the relationship
between FLI and CAD.
This cross-sectional study had some limitations. First,
the genders in our study could not be balanced in CAD
group: ratio of male to females was about 3:1. This is due
to the fact that CAD is more prevalent in males. Second,
CAD usually progresses for many years starting from
metabolic changes which may simultaneously affect the
occurrence of fatty liver. Actually, these two diseases do
not progress in parallel. In this study, the patients were all
diagnosed as CAD at first-time by coronary artery angiog-
raphy. However, the exact duration of the disease could
not be estimated. Third, majority of the patients in the
study were prescribed with anti-hyperlipidemia drugs such
as statin, etc. The potential effect of these drugs on both
CAD and fatty liver disease cannot be excluded. There-
fore, we performed the analysis adjusted for both anti-
hyperlipidemia and diabetic mellitus to minimize such
possibility. Finally, Neyman bias may exist to affect the
results due to the nature of study design.
Conclusions
FLI showed good correlation with NAFLD in patients
who underwent coronary angiography. Although we did
not find a relationship between FLI with newly diagnosed
CAD in the present study, our results did not exclude the
presence of correlation between FLI and cardiovascular
disease which was already proved in general population
[24,25]. With the rapid change in lifestyle, CAD becomes
healthy and economic burden and one of the leading
causes of death in Chinese. Recently, a cross-sectional
study representative sample of 46,239 Chinese adults over
20 years of age showed that the awareness, treatment, and
control of high total cholesterol were 11.0%, 5.1%, and2.8%, respectively [27]. This indicates that a large sub-
population would be susceptible to the development of
CAD. The certain relationship between FLI and CAD is still
awaited to be further clarified by the results of some large,
prospective studies in Chinese population in the future.
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